CASI Pharmaceuticals (CASIF) Shares Outstanding (Weighted Average) (2020 - 2025)

CASI Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 6 years, with the latest figure at $18.5 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 20.85% year-over-year to $18.5 million; the trailing twelve-month figure through Dec 2025 stood at $18.5 million (up 20.85% YoY), and the FY2025 full-year result was $18.5 million, up 20.85% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $18.5 million, up from $2.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $18.5 million in Q4 2025, with the low at $690.0 in Q1 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $9.0 million across 5 years, with a median of $13.3 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) slumped 99.98% — and 2023, when it jumped 443759.97%.
• CASI Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $13.6 million in 2021, then tumbled by 99.98% to $3010.0 in 2022, then jumped by 443759.97% to $13.4 million in 2023, then rose by 14.82% to $15.3 million in 2024, then climbed by 20.85% to $18.5 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $18.5 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025), per Business Quant data.